Genzyme cutting jobs at newly-acquired Bone Care

Just weeks after completing a deal to buy Bone Care International for $719 million, Genzyme announced it will hand out pink slips to about 40 employees. Most of the workers had been employed in various administrative duties. Genzyme says it plans to retain Bone Care's laboratory facility and most of its scientists. Bone Care sold a drug that restores kidney patients' vitamin D levels.

- read this report in the Milwaukee Journal-Sentinel for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.